Terms: = Breast cancer AND H3F3B, H3_3A, 3021, ENSG00000132475, P84243, H3_3B, MGC87783, MGC87782, H3F3 AND Treatment
7 results:
1. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
2. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract] [Full Text] [Related]
3. Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage breast cancer: A Network Meta-analysis.
John P; Osani MC; Kodali A; Buchsbaum R; Bannuru RR; Erban JK
Clin Breast Cancer; 2021 Feb; 21(1):e22-e37. PubMed ID: 32917538
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the breast International Group Trial 1-98.
Kensler KH; Regan MM; Heng YJ; Baker GM; Pyle ME; Schnitt SJ; Hazra A; Kammler R; Thürlimann B; Colleoni M; Viale G; Brown M; Tamimi RM
Breast Cancer Res; 2019 Feb; 21(1):30. PubMed ID: 30795773
[TBL] [Abstract] [Full Text] [Related]
5. The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China.
Zheng S; Song QK; Ren Y; Feng WL; Kong YN; Huang R; Xu F; Li J; Zhang BN; Fan JH; He JJ; Qiao YL
Appl Immunohistochem Mol Morphol; 2014; 22(5):383-9. PubMed ID: 24162264
[TBL] [Abstract] [Full Text] [Related]
6. Do thyroid disorders increase the risk of breast cancer?
Simon MS; Tang MT; Bernstein L; Norman SA; Weiss L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone K; Marchbanks PA; McDonald JA; Strom BL; Wilson HG; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1574-8. PubMed ID: 12496046
[TBL] [Abstract] [Full Text] [Related]
7. Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells.
Laurance ME; Starr DB; Michelotti EF; Cheung E; Gonzalez C; Tam AW; Deikman J; Edwards CA; Bardwell AJ
Nucleic Acids Res; 2001 Feb; 29(3):652-61. PubMed ID: 11160886
[TBL] [Abstract] [Full Text] [Related]
